AstraZeneca study shows benefits of asthma drug benralizumab

AstraZeneca has announced new phase III clinical trial data showing how its new compound benralizumab can help reduce the treatment burden for severe asthma patients.
 
In the ZONDA trial, adding benralizumab to the standard of care was shown to allow patients dependent on oral corticosteroid (OCS) therapy to significantly reduce or discontinue steroids, while maintaining asthma control.
 
Patients treated with benralizumab were more than four times as likely to reduce their OCS dose than those in the placebo group, meaning the study was able to meet its primary efficacy endpoint.
 
Data from the ZONDA trial will be included alongside findings from the pivotal phase III SIROCCO and CALIMA studies in future regulatory submissions for benralizumab.
 
Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We have shown benralizumab delivers a clinically meaningful OCS reduction alongside a substantial reduction in asthma exacerbation rate, including emergency treatment or hospitalisations, in this difficult-to-treat patient population."
 
Benralizumab is not yet approved anywhere in the world, but is under regulatory review in the US, EU, Japan and several other countries.
 
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.